Get the Stockscreener App
1.91
0.80%
0.035
Genenta Science Spa Adr stock is traded at $1.91, with a volume of 15,050.
It is up +0.80% in the last 24 hours and down -23.17% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
See More
Previous Close:
$1.875
Open:
$1.86
24h Volume:
15,050
Relative Volume:
0.02
Market Cap:
$44.76M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-3.6202
EPS:
-0.5276
Net Cash Flow:
$-6.76M
1W Performance:
-5.97%
1M Performance:
-23.17%
6M Performance:
-56.05%
1Y Performance:
-64.04%
1-Day Range:
$1.86
$2.07
1-Week Range:
$1.80
$2.20
52-Week Range:
$1.35
$10.00
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
1.91 | 43.58M | 0 | -9.64M | -6.76M | -0.5276 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.83 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
728.89 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.33 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
904.45 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.85 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Resumed | ROTH MKM | Buy |
| Jul-25-22 | Initiated | H.C. Wainwright | Buy |
| Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
Healthy Upside Potential: Genenta Science SpA ADR (GNTA) - Setenews
Genenta Science stock soars after update on glioblastoma treatment study By Investing.com - Investing.com Nigeria
Genenta Science stock soars after update on glioblastoma treatment study - Investing.com
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - GlobeNewswire Inc.
Genenta Science (NASDAQ:GNTA) Shares Down 3.4% – Should You Sell? - Defense World
Candlestick signals on Genenta Science S.p.A. Depositary Receipt stock todayProduct Launch & Short-Term Trading Opportunity Alerts - newser.com
Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX) - The Globe and Mail
Genenta Science Expands Board and Corporate Purpose Following Shareholders’ Meeting - MSN
Weiss Ratings Reiterates Sell (D-) Rating for Genenta Science (NASDAQ:GNTA) - MarketBeat
Genenta Science (NASDAQ:GNTA) Stock Price Down 4.7%What's Next? - MarketBeat
Genenta Science Appoints New Board Member and Confirms CEO - MSN
Genenta Science Secures $15 Million in Registered Direct Offering - The Globe and Mail
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - inkl
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com UK
United States shares higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com India
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com
Genenta Science stock plunges after $15 million ADS offering - Investing.com
Genenta Science stock plunges after $15 million ADS offering By Investing.com - Investing.com South Africa
Genenta Science appoints Dr. Francesco Galimi to board and approves 2024 financials By Investing.com - Investing.com South Africa
Genenta Science appoints Dr. Francesco Galimi to board and approves 2024 financials - Investing.com Philippines
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com UK
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com India
US Stock Market today: Dow, Nasdaq, S&P 500 open higher as US inflation data fuels Fed rate cut bets — Details here - Mint
Genenta Science Reports Reduced Losses and Strengthened Balance Sheet for H1 2025 - TipRanks
Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update - MarketBeat
Can Genenta Science S.p.A. (Common Stock) (K5F) stock hold up in economic slowdownGap Down & Community Driven Trade Alerts - newser.com
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Stock Price Down 1.9%Here's What Happened - MarketBeat
Analyzing Genenta Science S.p.A. Depositary Receipt with multi timeframe chartsWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genenta Science S.p.A. Announces Shareholders’ Meeting for Strategic Amendments - TipRanks
Genenta Science (NASDAQ:GNTA) Trading 7.4% HigherHere's Why - MarketBeat
Real time alert setup for Trinity Capital Inc. performanceJuly 2025 Drop Watch & Capital Protection Trading Alerts - Newser
Using data filters to optimize entry into Genenta Science S.p.A. Depositary ReceiptJuly 2025 News Drivers & High Accuracy Investment Signals - Newser
Assembly Biosciences Inc. stock trend outlook and recovery pathGDP Growth & Safe Capital Growth Tips - Newser
Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics - MSN
Genenta Science (NASDAQ:GNTA) Trading 7.4% Higher – Time to Buy? - Defense World
Will Genenta Science S.p.A. Depositary Receipt stock go up soonJuly 2025 News Drivers & Entry and Exit Point Strategies - Newser
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):